Preferred Label : semaglutide;
UNII : 53AXN4NNHX;
InChIKey : DLSWIYLPEUIQAV-CCUURXOWSA-N;
Origin ID : C000591245;
UMLS CUI : C3885068;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-janvier-2025-13-16-janvier
2025
false
false
false
France
French
Toxic Optic Neuropathy
Nonarteritic anterior ischemic optic neuropathy
semaglutide
risk assessment
risk
semaglutide
drug information
europe
injections, subcutaneous
Glucagon-Like Peptide-1 Receptor Agonists
product surveillance, postmarketing
---
https://www.cbip.be/fr/articles/4238?folia=4237
2024
false
false
false
Belgium
French
journal article
obesity
treatment outcome
semaglutide
risks and benefits
Benefit-Risk assessment
cardiovascular diseases
---
https://minerva-ebp.be/FR/Analysis/878
2024
Belgium
critical appraisal or critical reading
obesity
condom
semaglutide
heart failure
cardiac ejection fraction
obesity
obesity, nos
condoms
semaglutide
heart failure, nos
---
https://ansm.sante.fr/actualites/analogues-du-glp-1-et-obesite-nous-prenons-des-mesures-pour-securiser-leur-utilisation-en-france
2024
false
false
false
France
French
patient safety
Glucagon-Like Peptide-1 Receptor Agonists
obesity
france
Drug Misuse
prescription drug misuse
drug prescriptions
critical pathways
semaglutide
Wegovy
pharmacovigilance note
guideline
Saxenda
---
https://www.has-sante.fr/jcms/p_3562976/fr/wegovy-semaglutide-obesite
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
Glucagon-Like Peptide-1 Receptor Agonists
semaglutide
adult
body mass index
evaluation of the transparency committee
obesity
semaglutide
---
https://ansm.sante.fr/tableau-atu-rtu/wegovy-solution-injectable-en-stylo-prerempli
2024
false
false
false
France
French
drug information
semaglutide
adult
obesity
weight loss
body mass index
risk factors
comorbidity
summary of product characteristics
package leaflet
guidelines for drug use
patients guideline
continuity of patient care
pregnancy
injections, subcutaneous
---
https://www.usherbrooke.ca/baladocritique/archives/episode-59-etude-select
2024
Canada
sound
Diastolic Blood Pressure
semaglutide
Obesity, CTCAE
Cardiovascular Disorder
data collection
Off Study
obesity
disease of cardiovascular system, nos
breeding
Clinical Study
semaglutide
obesity
Obesity
Have Diabetes
Human Participant Protection Regulations
DICOM Study
obesity, nos
cardiovascular diseases
diabetes mellitus
persons
Semaglutide
Obese
On Study
---
https://www.usherbrooke.ca/baladocritique/archives/episode-64-etude-flow
2024
France
sound
episode of
diabetes non-insulin dependent
chronic renal failure syndrome, nos
semaglutide
semaglutide
diabetes mellitus, type 2
data collection
renal insufficiency, chronic
glycosuria, renal
---
https://minerva-ebp.be/FR/Article/2387
2024
Belgium
critical appraisal or critical reading
obesity
adulthood
Usual Severity Weight Loss
Obese
semaglutide
How Much Distress Weight Loss
Weight Lifting
Illinois
How Often Weight Loss
weight loss
Semaglutide
Interleukin
weight loss
semaglutide
Weight Loss
Overweight
Israel
What Month is it
mouth, nos
adult
Oral Cavity
Oral Route of Administration
Oral Dosage Form
Legal Adult
Have Weight Loss
decreased body weight
overweight
Weight Loss, CTCAE
---
https://ansm.sante.fr/actualites/obesite-quel-profil-dutilisation-de-wegovy-en-france-pendant-son-acces-precoce
2024
false
false
false
France
French
drug information
obesity
Wegovy
semaglutide
Product containing only semaglutide in parenteral dose form (medicinal product form)
drug utilization review
Glucagon-Like Peptide-1 Receptor Agonists
pharmacoepidemiology
france
drug utilization
---
https://www.has-sante.fr/jcms/p_3465412/fr/wegovy-semaglutide-obesite
2023
false
false
false
France
French
evaluation of the transparency committee
semaglutide
semaglutide
obesity
---
https://ansm.sante.fr/informations-de-securite/lema-alerte-sur-la-circulation-de-stylos-ozempic-falsifies-semaglutide-1mg-solution-injectable-en-europe
2023
false
false
false
France
French
pharmacovigilance note
counterfeit drugs
europe
Falsified Drugs
guideline
semaglutide
---
https://ansm.sante.fr/actualites/diabete-de-type-2-et-tensions-dapprovisionnement-conduite-a-tenir-pour-la-prescription-des-analogues-de-glp1
2023
false
false
false
France
French
incretins
Glucagon-Like Peptide-1 Receptor
guideline
semaglutide
semaglutide
continuity of patient care
hypoglycemic agents
diabetes mellitus, type 2
guidelines for drug use
Liraglutide
break in supply
liraglutide
---
https://www.has-sante.fr/jcms/p_3453304/fr/wegovy-semaglutide-obesite
2023
false
false
false
France
semaglutide
insurance, health, reimbursement
treatment outcome
Glucagon-like peptide 1 receptor agonist (disposition)
adult
Class 3 Obesity
obesity, morbid
comorbidity
evaluation of the transparency committee
obesity
semaglutide
---
https://ansm.sante.fr/actualites/ozempic-semaglutide-un-medicament-a-utiliser-uniquement-dans-le-traitement-du-diabete-de-type-2
2023
false
false
false
France
French
Off-Label use
semaglutide
injections, subcutaneous
hypoglycemic agents
weight loss
drug overdose
pharmacovigilance note
guideline
guidelines for drug use
diabetes mellitus, type 2
Glucagon-Like Peptide-1 Receptor
Prescription Drug Monitoring Programs
---
https://minerva-ebp.be/FR/Article/2341
2023
Belgium
critical appraisal or critical reading
administrators
Adolescent
adolescent
Adolescent
has patient
semaglutide
semaglutide
organization and administration
adolescence
patients
administration
administrative personnel
Administration
---
https://www.has-sante.fr/jcms/p_3398698/fr/wegovy-semaglutide-obesite
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
Glucagon-Like Peptide-1 Receptor
adult
overweight
body mass index
evaluation of the transparency committee
obesity
semaglutide
---
https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
semaglutide
semaglutide
obesity
overweight
drug approval
europe
body mass index
adult
injections, subcutaneous
Glucagon-Like Peptide-1 Receptor
Glucagon-like peptide 1 receptor agonist (disposition)
product surveillance, postmarketing
aged
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
Product containing only semaglutide in parenteral dose form (medicinal product form)
---
https://www.has-sante.fr/jcms/p_3333274/fr/ozempic-semaglutide-diabete-type-2
2022
France
evaluation of the transparency committee
Diabetes mellitus type 2
diabetes mellitus, type 2
Ozempic
semaglutide
diabetes non-insulin dependent
semaglutide
---
https://minerva-ebp.be/FR/Analysis/774
2022
Belgium
critical appraisal or critical reading
Diabetes mellitus type 2
semaglutide
administrative personnel
organization and administration
weight loss
decreased body weight
weight loss
empagliflozin
diabetes mellitus, type 2
semaglutide
Administration
has patient
administration
patients
administrators
blood glucose
empagliflozin
disease
diabetes non-insulin dependent
---
https://www.has-sante.fr/jcms/p_3359590/fr/wegovy-semaglutide-obesite
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
comorbidity
injections, subcutaneous
Product containing only semaglutide in parenteral dose form (medicinal product form)
Glucagon-Like Peptide-1 Receptor
evaluation of the transparency committee
obesity
semaglutide
---
https://minerva-ebp.be/FR/Article/2237
2021
false
false
false
Belgium
critical appraisal or critical reading
Adult
body weight
semaglutide
Diabetes
diabetes mellitus
exercise
glucagon-like peptide 1
dietetics
association
adulthood
nutritionists
measures
Adult
semaglutide
overweight
glucagon-like peptide 1
adult
diabetes mellitus, nos
weights and measures
---
https://www.has-sante.fr/jcms/p_3282761/fr/rybelsus-7-14-mg-semaglutide
2021
false
false
false
France
evaluation of the transparency committee
Product containing precisely semaglutide 3 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely semaglutide 7 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely semaglutide 14 milligram/1 each conventional release
oral tablet (clinical drug)
diabetes mellitus, type 2
hypoglycemic agents
semaglutide
Glucagon-Like Peptide-1 Receptor
semaglutide
glucagon-like peptides
treatment outcome
insurance, health, reimbursement
administration, oral
---
https://www.has-sante.fr/jcms/p_3282782/fr/ozempic-semaglutide
2021
false
false
false
France
evaluation of the transparency committee
Ozempic
semaglutide
semaglutide
---
https://www.cbip.be/fr/articles/3625?folia=3622
2021
false
false
false
Belgium
French
journal article
drug information
administration, oral
semaglutide
GLP-1 Mimetics
diabetes mellitus, type 2
pharmaceutic aids
salcaprozate sodium
treatment outcome
Product containing precisely semaglutide 7 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely semaglutide 14 milligram/1 each conventional release
oral tablet (clinical drug)
semaglutide
body weight
hypoglycemic agents
hypoglycemic agents
semaglutide
N-(8-(2-hydroxybenzoyl)amino)caprylate
glucagon-like peptides
glucagon-like peptides
caprylates
---
https://www.usherbrooke.ca/baladocritique/archives/episode-40-etude-step1/
2021
Canada
sound
safety
persons
obesity, nos
semaglutide
obesity
Obesity
data collection
Ketoacidosis
episode of
Obesity
obesity
Safety
glucagon-like peptides
---
https://www.cfp.ca/content/67/11/e296
2021
Canada
journal article
weight loss
semaglutide
semaglutide
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
semaglutide
semaglutide
semaglutide
diabetes mellitus, type 2
adult
administration, oral
Product containing only semaglutide in oral dose form (medicinal product form)
Glucagon-Like Peptide-1 Receptor
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
glucagon-like peptides
glucagon-like peptides
---
https://www.has-sante.fr/jcms/p_3225389/fr/rybelsus
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
semaglutide
semaglutide
semaglutide
Glucagon-like peptide 1 receptor agonist (disposition)
Glucagon-Like Peptide-1 Receptor
administration, oral
diabetes mellitus, type 2
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides
---
https://www.has-sante.fr/portail/jcms/c_2906429/fr/ozempic
https://www.has-sante.fr/portail/jcms/c_2906429/fr/ozempic-semaglutide-antidiabetique
2019
false
false
false
France
treatment outcome
semaglutide
semaglutide
semaglutide
injections, subcutaneous
insurance, health, reimbursement
adult
diabetes mellitus, type 2
drug therapy, combination
guidelines for drug use
metformin
insulin
sulfonylurea compounds
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides
---
https://www.has-sante.fr/jcms/c_2906429/fr/ozempic
2019
false
false
false
France
semaglutide
semaglutide
semaglutide
diabetes mellitus, type 2
drug therapy, combination
metformin
Glucagon-Like Peptide-1 Receptor
adult
injections, subcutaneous
treatment outcome
hypoglycemic agents
sulfonylurea compounds
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides
---
https://www.ema.europa.eu/medicines/human/EPAR/Ozempic
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
semaglutide
semaglutide
drug approval
europe
treatment outcome
adult
diabetes mellitus, type 2
injections, subcutaneous
Pre-filled Pen Syringe
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
cardiovascular diseases
diabetes complications
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
semaglutide
glucagon-like peptides
glucagon-like peptides
---
